VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 366 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2013. The put-call ratio across all filers is 0.62 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $4,750,000 | +26.8% | 204,197 | -13.3% | 0.33% | +21.0% |
| Q1 2018 | $3,745,000 | -39.0% | 235,437 | -19.8% | 0.27% | -19.3% |
| Q4 2017 | $6,142,000 | -66.8% | 293,737 | +182.1% | 0.34% | -78.8% |
| Q3 2015 | $18,501,000 | +101.0% | 104,133 | +151.1% | 1.58% | +132.3% |
| Q2 2015 | $9,205,000 | -25.7% | 41,477 | -33.8% | 0.68% | -25.5% |
| Q1 2015 | $12,381,000 | +902.5% | 62,667 | +542.7% | 0.92% | +1073.1% |
| Q2 2014 | $1,235,000 | -93.6% | 9,750 | -93.3% | 0.08% | -94.3% |
| Q1 2014 | $19,244,000 | -20.9% | 146,040 | -29.6% | 1.36% | -20.5% |
| Q4 2013 | $24,322,000 | +11.5% | 207,371 | -0.7% | 1.71% | +4.9% |
| Q3 2013 | $21,821,000 | +6.8% | 208,845 | -12.2% | 1.63% | -0.9% |
| Q2 2013 | $20,440,000 | – | 237,779 | – | 1.65% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,577,892 | $994,984,000 | 31.62% |
| Ruane, Cunniff & Goldfarb | 33,922,192 | $6,051,041,000 | 31.06% |
| LeVasseur Capital Partners LLC | 162,394 | $28,968,000 | 29.76% |
| FARLEY CAPITAL L.P. | 192,130 | $34,272,000 | 27.18% |
| Pershing Square Capital Management | 19,473,933 | $3,473,760,000 | 24.90% |
| Arrow Capital Management, LLC | 109,461 | $19,525,000 | 16.53% |
| Marble Arch Investments | 1,196,900 | $213,503,000 | 16.43% |
| Tesuji Partners | 1,368,040 | $244,414,000 | 15.82% |
| ValueAct Holdings | 14,994,261 | $2,674,676,000 | 15.55% |
| Hound Partners | 3,898,648 | $695,441,000 | 15.04% |